跳至主要内容
临床试验/NCT01209416
NCT01209416已完成不适用

The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

University of Aarhus1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
8
试验地点
1
主要终点
Effects of ghrelin during basal and hyperinsulinemic conditions

研究概览

简要总结

This study will investigate the non-growth-hormone-dependent metabolic effects of the hormone Ghrelin in growth hormone deficient subjects by examining the insulin tolerance as well as signal proteins in fat and muscle biopsies.

详细描述

Ghrelin is a relatively 'new' hormone that is produced in the stomach and to a lesser extend in the hypothalamus of the brain. The actions of ghrelin are diverse and includes stimulation of the appetite center of the brain and the release of growth hormone. We have for the first time shown that ghrelin also stimulates the metabolism of fatty acids and induces insulin resistance in skeletal muscle. These effects have we confirmed in growth hormone deficient subjects on a stabile substitution treatment with growth hormone and hydrocortisone. With these subjects we can investigate the effects of ghrelin that are independent of growth hormone. The present study is a continuation of these findings, as we wish to investigate whether the insulin resistance effect of ghrelin is dependent of the concomitant metabolism of fatty acids. This is possible by administration of the niacin acid antagonist Acipimox, that blocks the fatty acid metabolism reversibly. We have applied this experimental principle in other settings with success.

Knowledge of the effects of ghrelin in general can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • males with hypopituitarism in regard to growth hormone and ACTH in stabile treatment regime
  • age 18-65
  • BMI 20-35

排除标准

  • abuse of alcohol
  • malign disease
  • medication other than that expected for hypopituitarism
  • known disease other than hypopituitarism
  • participation in isotope investigations the last 6 months

研究组 & 干预措施

Ghrelin / Acipimox

Active Comparator

Ghrelin infusion and tablet acipimox

干预措施: Acipimox (Drug)

Ghrelin / Acipimox

Active Comparator

Ghrelin infusion and tablet acipimox

干预措施: Ghrelin (Drug)

Ghrelin / placebo

Active Comparator

Ghrelin infusion and placebo tablets

干预措施: Ghrelin (Drug)

Ghrelin / placebo

Active Comparator

Ghrelin infusion and placebo tablets

干预措施: Placebo (Other)

Placebo / Acipimox

Active Comparator

saline infusion and tablet Acipimox

干预措施: Acipimox (Drug)

Placebo / Acipimox

Active Comparator

saline infusion and tablet Acipimox

干预措施: Placebo (Other)

Placebo / placebo

Placebo Comparator

saline infusion and placebo tablets

干预措施: Placebo (Other)

结局指标

主要结局

Effects of ghrelin during basal and hyperinsulinemic conditions

时间窗: 5 hours investigation day

Effects of ghrelin on thirst, fluid intake, urine production and natriuresis

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验